3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Melanoma
51
Neoplasm Metastasis
19
Skin Neoplasms
15
Carcinoma, Renal Cell
13
Leukemia, Myeloid, Acute
12
Kidney Neoplasms
11
Leukemia
9
Neoplasms
7
Uterine Cervical Neoplasms
5
Lymphoma
5
Congenital Abnormalities
5
Breast Neoplasms
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Neuroblastoma
4
Myelodysplastic Syndromes
4
Lymphoma, Non-Hodgkin
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Carcinoma, Non-Small-Cell Lung
4
Vaginal Neoplasms
2
Penile Neoplasms
2
Papillomavirus Infections
2
Oropharyngeal Neoplasms
2
Melanoma, Experimental
2
Lymphoma, Mantle-Cell
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Erythroblastic, Acute
2
Brain Neoplasms
2
Interventions
fludarabine phosphate
43
Whole-Body Irradiation
36
Mycophenolic Acid
36
Peripheral Blood Stem Cell Transplantation
31
Cyclophosphamide
31
Tacrolimus
28
Busulfan
22
Antilymphocyte Serum
21
Cyclosporine
19
fludarabine
17
ruxolitinib
16
Melphalan
16
Methotrexate
15
Cytarabine
12
thymoglobulin
9
Sirolimus
9
Etoposide
9
Granulocyte Colony-Stimulating Factor
8
Filgrastim
8
Cyclosporins
8
Radiotherapy
7
Cord Blood Stem Cell Transplantation
7
Rituximab
6
Alemtuzumab
6
merphos
5
Stem Cell Transplantation
5
Flow Cytometry
5
Azacitidine
5
sargramostim
4
ponatinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Myeloproliferative Disorders
×
aldesleukin
×
Clear all
NCT00539695
2018-05-04
IL2 for GVHD
Baylor College of Medicine
Phase 2
Completed
25 enrolled
7 charts